TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34106599

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 252

Group type: COMPARATOR
Intervention: Rehabilitation training
Number of subjects: 252
Study: 34494681

Group type: EXPERIMENTAL
Intervention: Telephone behavioral health counseling
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Clinic-based behavioral health counseling
Number of subjects: 240

Group type: COMPARATOR
Intervention: Attention control nutrition education
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Clinic-based counseling
Number of subjects: 240
Study: 32878820

Group type: EXPERIMENTAL
Intervention: Pirarubicin (THP)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 103
Study: 35197018

Group type: EXPERIMENTAL
Intervention: Goldilocks Work intervention
Number of subjects: 28
Study: 32913130

Group type: EXPERIMENTAL
Intervention: Mindfulness Skills for Students (MSS)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Support as usual (SAU)
Number of subjects: 616
Study: 32996842

Group type: EXPERIMENTAL
Intervention: Web-based legacy intervention (digital storyboards, legacy questions, photographs, video, music)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (wait-list control)
Number of subjects: 150
Study: 36401233

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonide (IVTA) combined with standard phacoemulsification surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine phacoemulsification surgery (Control)
Number of subjects: 50
Study: 36196727

Group type: EXPERIMENTAL
Intervention: Vitamin D and omega-3 polyunsaturated fatty acid (PUFA) co-supplementation (VIDOM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33444116

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) plus Bevacizumab (5 mg/kg) every 2 weeks (CPB arm)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) without Bevacizumab (CP arm)
Number of subjects: 114
Study: 32559656

Group type: EXPERIMENTAL
Intervention: Positive feedback on ToM performance
Number of subjects: 131

Group type: COMPARATOR
Intervention: Negative feedback on ToM performance
Number of subjects: 131

Group type: COMPARATOR
Intervention: No feedback on ToM performance
Number of subjects: 131
Study: 36378308

Group type: EXPERIMENTAL
Intervention: Quaternary ammonium, salt‐based, 24‐hour continuously active germicidal wipe
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine disinfection (Control)
Number of subjects: 50
Study: 32050238

Group type: EXPERIMENTAL
Intervention: White-to-white (WTW) distance measurement
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Horizontal WTW measurement without adjustment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vertical STS meridian measurement
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Use of AS-OCT
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: AC IOL placement orientation
Number of subjects: 65
Study: 36473191

Group type: EXPERIMENTAL
Intervention: Topical Cyclosporin A 0.1% (CsA), once daily for 12 weeks
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Topical Diquafosol Tetrasodium 3% (DQS), six times a day for 12 weeks
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Combination of CsA and DQS, for 12 weeks
Number of subjects: 279
Study: 34051812

Group type: EXPERIMENTAL
Intervention: 6-gene prediction model for AML survival
Number of subjects: 0
Study: 32919916

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan therapy
Number of subjects: 8399

Group type: COMPARATOR
Intervention: ICD use
Number of subjects: 8399
Study: 33208340

Group type: EXPERIMENTAL
Intervention: Paclitaxel (P) weekly × 12 plus carboplatin AUC6 every 21 days × 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days × 4 (CbP → AC, arm A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC6 + docetaxel (D) every 21 days × 6 (CbD, arm B)
Number of subjects: 100
Study: 35442870

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 85
Study: 33452004

Group type: EXPERIMENTAL
Intervention: FIL200 + MTX
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: FIL100 + MTX
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: FIL200 monotherapy
Number of subjects: 1252

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 1252
Study: 33998550

Group type: EXPERIMENTAL
Intervention: Upper limbs cycle ergometer (ULCE) combined with conventional physiotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 20
Study: 32600764

Group type: COMPARATOR
Intervention: 0% glucose inclusion (L1, n = 20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10% glucose inclusion (L2, n = 20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20% glucose inclusion (L3, n = 20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30% glucose inclusion (L4, n = 20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 40% glucose inclusion (L5, n = 20)
Number of subjects: 100
Study: 34327739

Group type: EXPERIMENTAL
Intervention: GSK3335065 (1.3 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study: 33938787

Group type: EXPERIMENTAL
Intervention: CPAP plus usual care (n=55)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care alone (control, n=54)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CPAP group (n=55)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (n=54)
Number of subjects: 108
Study: 32453369

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg orally twice daily for 2 years (n=133)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo (n=128)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 36350138

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm (random forest model) for predicting optimal cytoreduction (<1 cm) and no gross residual (RD = 0 mm).
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm (random forest model) for predicting no gross residual (RD = 0 mm).
Number of subjects: 151
Study: 34162759

Group type: EXPERIMENTAL
Intervention: Maccabi Telecare Center (MTC) intervention
Number of subjects: 0
Study: 35930057

Group type: EXPERIMENTAL
Intervention: Repetitive shocks (3×5 minutes)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Random vibration (1×5 minutes)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Repetitive shocks
Number of subjects: 8
Study: 32012231

Group type: EXPERIMENTAL
Intervention: Radotinib 300 mg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Radotinib 400 mg
Number of subjects: 241

Group type: COMPARATOR
Intervention: Imatinib 400 mg
Number of subjects: 241
Study: 36438801

Group type: EXPERIMENTAL
Intervention: 15 mg/kg of vancomycin every 12 h
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 15 mg/kg of vancomycin every 8 h
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (every 12 h)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (every 8 h)
Number of subjects: 56
Study: 33188423

Group type: EXPERIMENTAL
Intervention: Refined rice bran, flaxseed, and sesame seed oils (30 g per day for 8 weeks)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Refined olive oil (control)
Number of subjects: 143
Study: 33963734

Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF) and amoxicillin along with standard nutrition counseling for 2-12 weeks
Number of subjects: 573

Group type: COMPARATOR
Intervention: Nutrition counseling alone for 6 weeks
Number of subjects: 573
Study: 35188267

Group type: EXPERIMENTAL
Intervention: Raspberry leaf tea (RLT)
Number of subjects: 121
Study: 34506503

Group type: EXPERIMENTAL
Intervention: Community-based delivery without a short text reminder
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Community-based delivery with a short message reminder (SMS)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Community-based delivery without SMS
Number of subjects: 375

Group type: COMPARATOR
Intervention: Facility-based delivery without a short text reminder (Control)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Facility-based delivery with a short message reminder
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Community-based delivery utilizing Community Health Workers (CHWs)
Number of subjects: 375
Study: 36241705

Group type: EXPERIMENTAL
Intervention: RDN
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 80
Study: 32870416

Group type: EXPERIMENTAL
Intervention: Peer-mediated intervention (PLF) for 10 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 68
Study: 33361021

Group type: EXPERIMENTAL
Intervention: MAO‐B inhibitor (Selegiline 5 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Donepezil (DNP 10 mg daily)
Number of subjects: 120
Study: 36435988

Group type: EXPERIMENTAL
Intervention: CII elastics (100-150 g/side), full time
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no CII elastics)
Number of subjects: 43
Study: 33177131

Group type: EXPERIMENTAL
Intervention: Deep electroacupuncture with strong deqi
Number of subjects: 44

Group type: COMPARATOR
Intervention: Shallow electroacupuncture with no deqi
Number of subjects: 44
Study: 33611331

Group type: EXPERIMENTAL
Intervention: Guided self-massage (10 minutes)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (fabric ring massage)
Number of subjects: 73
Study: 32795086

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study: 35805761

Group type: EXPERIMENTAL
Intervention: Auto-generated summary text about HPV (n = 193)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Original text about HPV (n = 193)
Number of subjects: 386
Study: 34551936

Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33556410

Group type: EXPERIMENTAL
Intervention: RT + saffron supplement (150 mg after each session)
Number of subjects: 28

Group type: COMPARATOR
Intervention: RT + placebo (dextrose pill)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: RT + saffron supplement
Number of subjects: 28

Group type: COMPARATOR
Intervention: RT + placebo
Number of subjects: 28
Study: 33176899

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 9-OH-risperidone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Active moiety (combined concentrations)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Model-based predictions
Number of subjects: 108
Study: 32696559

Group type: EXPERIMENTAL
Intervention: risk-guided nurse intervention (DMP-Plus group)
Number of subjects: 404

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 404
Study: 36286887

Group type: EXPERIMENTAL
Intervention: Prebiotic treatment (Zacofalk) in subgroup Ia (n=58)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Enterosorbents in subgroup Ib (n=57)
Number of subjects: 230

Group type: COMPARATOR
Intervention: K-group (n=115) with respiratory symptoms
Number of subjects: 230
Study: 32340903

Group type: EXPERIMENTAL
Intervention: 16 g/d native inulin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 150
Study: 34436555

Group type: EXPERIMENTAL
Intervention: Web-based diet and lifestyle intervention utilizing short animated videos, delivered weekly for 5 weeks.
Number of subjects: 269
Study: 35114186

Group type: COMPARATOR
Intervention: 125 cc/h normal saline
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 250 cc/h normal saline
Number of subjects: 180
Study: 33608403

Group type: EXPERIMENTAL
Intervention: Use of insulin
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Diabetes-39 (D-39) questionnaire
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Hypertension comorbidity
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: HbA1c test
Number of subjects: 206
Study: 36499011

Group type: EXPERIMENTAL
Intervention: Rhubarb extract (RE) 12.5 mg per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rhubarb extract (RE) 25 mg per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study: 33963015

Group type: EXPERIMENTAL
Intervention: Adjuvant ipilimumab 3 mg/kg (ipi3)
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Adjuvant ipilimumab 10 mg/kg (ipi10)
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Grades 1-2 rash
Number of subjects: 1673
Study: 36314474

Group type: EXPERIMENTAL
Intervention: Individually tailored home-based physiotherapy program (12 weeks)
Number of subjects: 21
Study: 34332432

Group type: EXPERIMENTAL
Intervention: Assertive case management
Number of subjects: 592

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 592
Study: 35249863

Group type: EXPERIMENTAL
Intervention: New oral anticancer drugs
Number of subjects: 202
Study: 32510759

Group type: EXPERIMENTAL
Intervention: 6-week cognitive training intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECG-derived ANS segment at baseline
Number of subjects: 0
Study: 33414106

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher BMI (controlling for diabetes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 0
Study: 32805594

Group type: EXPERIMENTAL
Intervention: Manual milk administration by parents (MAP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Electric syringe administration (ESA)
Number of subjects: 15
Study: 36171608

Group type: EXPERIMENTAL
Intervention: Plastinated specimens
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Three-dimensional printed (3DP) models
Number of subjects: 96
Study: 33400237

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) group, n = 11; dose 40 × 10^6 Treg cells/kg of body weight
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) group, n = 3; dose 1.0 × 10^6 Treg cells
Number of subjects: 14

Group type: COMPARATOR
Intervention: IV group
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: IT group
Number of subjects: 14

Group type: COMPARATOR
Intervention: IV and IT groups
Number of subjects: 14
Study: 35114327

Group type: EXPERIMENTAL
Intervention: Advergame promoting fruit (n=43)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control condition (n=40)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Advergame promoting non-food products (n=40)
Number of subjects: 123
Study: 33773809

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Attention-control (AC)
Number of subjects: 144
Study: 32404132

Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation using Tymo system or Walker View in addition to traditional therapy
Number of subjects: 195

Group type: COMPARATOR
Intervention: Traditional rehabilitation program
Number of subjects: 195
Study: 35017258

Group type: EXPERIMENTAL
Intervention: Analgesic (ANA) treatment (metamizole/dipyrone) with observational learning (positive video)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment with observational learning (positive video)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Analgesic (ANA) treatment (metamizole/dipyrone) with neutral video
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment with neutral video
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no medication or observational learning)
Number of subjects: 150
Study: 34245136

Group type: EXPERIMENTAL
Intervention: Partial thickness flap
Number of subjects: 10

Group type: COMPARATOR
Intervention: Full thickness flap
Number of subjects: 10
Study: 32005277

Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation (ASV) therapy added to PCI and optimal medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy and PCI alone (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation (ASV) therapy
Number of subjects: 0
Study: 36369456

Group type: EXPERIMENTAL
Intervention: MenACWY liquid
Number of subjects: 2669

Group type: COMPARATOR
Intervention: MenACWY licensed
Number of subjects: 2669
Study: 33618779

Group type: EXPERIMENTAL
Intervention: Functional strength training for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control protocol without additional strength training
Number of subjects: 18
Study: 34034826

Group type: EXPERIMENTAL
Intervention: Capitation compensation mechanism
Number of subjects: 100
Study: 32130122

Group type: EXPERIMENTAL
Intervention: eHealth tool with electronic survey and tailored resources for physical activity (PA) prescription
Number of subjects: 530

Group type: COMPARATOR
Intervention: Usual care from PCP (control group)
Number of subjects: 530
Study: 35317830

Group type: EXPERIMENTAL
Intervention: Individualized home-based physical activity program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34962979

Group type: EXPERIMENTAL
Intervention: Edoxaban 60/30mg
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Edoxaban 30/15mg
Number of subjects: 841
Study: 32348101

Group type: EXPERIMENTAL
Intervention: Diosmin 600 mg once daily for 12 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard treatment with rivaroxaban for six months and ECS for 12 months
Number of subjects: 90
Study: 36501092

Group type: EXPERIMENTAL
Intervention: GTC+CCA (620 mg GTC, 373 mg CCA, and 119 mg caffeine/day) for three weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: PLA (0 mg GTC, 0 mg CCA, and 119 mg caffeine/day) for three weeks
Number of subjects: 11
Study: 34569438

Group type: EXPERIMENTAL
Intervention: CAU + SOS
Number of subjects: 250

Group type: COMPARATOR
Intervention: CAU
Number of subjects: 250
Study: 35688590

Group type: COMPARATOR
Intervention: Robot-assisted surgery (RAS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Kinematic alignment (KA)
Number of subjects: 300
Study: 33839919

Group type: EXPERIMENTAL
Intervention: Mediterranean diet group (MDG)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle group (MLG)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard care group (SCG)
Number of subjects: 180
Study: 32916291

Group type: EXPERIMENTAL
Intervention: Initial invasive strategy (cardiac catheterization and revascularization)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial conservative strategy (medical therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 0
Study: 34856913

Group type: EXPERIMENTAL
Intervention: Topical ozonated olive oil lotion
Number of subjects: 121

Group type: COMPARATOR
Intervention: Permethrin shampoo
Number of subjects: 121
Study: 33253864

Group type: COMPARATOR
Intervention: Placebo and miltefosine (P + M)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Topical GM-CSF and miltefosine (G + M)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Parenteral meglumine antimoniate (MA)
Number of subjects: 150
Study: 34239299

Group type: EXPERIMENTAL
Intervention: Pedometer-based behavioral intervention (IG)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 327
Study: 34956841

Group type: EXPERIMENTAL
Intervention: ROCO intervention plus care as usual
Number of subjects: 107

Group type: COMPARATOR
Intervention: Waiting control group receiving care as usual
Number of subjects: 107
Study: 33161684

Group type: EXPERIMENTAL
Intervention: First mobilization trial
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Second mobilization trial with plerixafor
Number of subjects: 87
Study: 32616150

Group type: EXPERIMENTAL
Intervention: Baroreflex Activation Therapy (BAT) plus optimal medical management
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (optimal medical management alone)
Number of subjects: 245
Study: 35869690

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg/m2/day (n = 32)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cyclosporine (CYC) 5 mg/kg/day (n = 34)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cyclosporine (CYC)
Number of subjects: 66
Study: 34170798

Group type: EXPERIMENTAL
Intervention: Multicomponent nursing intervention program focusing on modifiable risk factors
Number of subjects: 1749

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1749
Study: 32843517

Group type: EXPERIMENTAL
Intervention: Electronic safety-netting toolkit embedded in EMIS-Web
Number of subjects: 60
Study: 33740389

Group type: EXPERIMENTAL
Intervention: 1000 mg GSH per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33230526

Group type: EXPERIMENTAL
Intervention: CT-P13 s.c. 120 mg biweekly until W28
Number of subjects: 343

Group type: COMPARATOR
Intervention: CT-P13 i.v. 3 mg/kg every 8 weeks until W22
Number of subjects: 343
Study: 32297162

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus over 30 minutes, followed by 1 mg/kg/h continuous infusion for 6 hours post-surgery)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 41
Study: 35089354

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication regimens that stimulate type 2 and 4 angiotensin II receptors
Number of subjects: 8685

Group type: COMPARATOR
Intervention: Antihypertensive medication regimens that inhibit type 2 and 4 angiotensin II receptors
Number of subjects: 8685

Group type: EXPERIMENTAL
Intervention: Stimulating-only antihypertensive medications
Number of subjects: 8685

Group type: COMPARATOR
Intervention: Inhibiting-only antihypertensive medications
Number of subjects: 8685